The need to raise more capital to fund product development, and the associated dilution, was the last piece of bad news that the company was clearly going to have to announce. Given that is out of the way, going forward news should be positive and it is time to go long.
Now you tell them? Just because Arikayce will not be sold for CF in the USA or that sales -IF approved_ for NTM will not start for more than 3 years and that the money raised they will burn and that the EU may require more info or that .... with posts like yours I am sure most feel better. I say there will be more bad news,but hen again I am just playing the odds in biotech